Skip to main content
SpringerLink
Log in

Expression of Cell Cycle Regulatory Proteins in Breast Carcinomas Before and After Preoperative Chemotherapy

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Molecular markers predicting response to preoperative chemotherapy would be of major clinical relevance in breast cancer. Therefore, we studied the relationship between the expression of cell cycle regulatory proteins and clinical outcome in breast cancer patients receiving preoperative chemotherapy. Expression of p21Waf1, p27Kip1, p53, cyclin D3 and Ki-67 was determined in breast carcinomas by means of immunohistochemistry both prior and after preoperative chemotherapy. Expression data were compared with both clinical parameters and response to preoperative chemotherapy with either cyclophosphamide/methotrexate/5-fluorouracil (CMF, n = 29) or epirubicin/docetaxel (ED, n = 36). In paired samples before and after preoperative chemotherapy, the percentage of p21Waf1, p27Kip1, p53 and cyclin D3 positive nuclei of tumor cells in postchemotherapy specimens was significantly higher than the percentage in prechemotherapy samples but no change in Ki-67 expression was observed. High Ki-67 expression (p = 0.02), negative estrogen receptor status (p = 0.01) and negative progesterone receptor status (p = 0.04) were associated with complete pathologic response to chemotherapy, whereas the other markers did not predict response. In conclusion, expression levels of p21Waf1, p27Kip1, p53 and cyclin D3 significantly increased after preoperative chemotherapy in breast carcinomas but only high Ki-67 expression, negative estrogen receptor status and negative progesterone receptor status were associated with complete pathologic response to preoperative chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998

    Google Scholar 

  2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L: Preoperative chemotherapy in operable breast cancer. Lancet 341: 1485, 1993

    Google Scholar 

  3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998

    Google Scholar 

  4. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997

    Google Scholar 

  5. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, Williams J: Cell-cycle arrest versus cell death in cancer therapy. Nat Med 3: 1034-1036, 1997

    Google Scholar 

  6. Ruan S, Okcu MF, Ren JP, Chiao P, Adreeff M, Levin V, Zhang W: Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 58: 1538-1543, 1998

    Google Scholar 

  7. St. Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumour cells to anticancer agents. Nat Meda 2: 1204-1210, 1996

    Google Scholar 

  8. Elledge RM, Allred DC: Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52: 79-98, 1998

    Google Scholar 

  9. Thor AD, Liu S, Moore DH, Shi Q, Edgerton SM: p21WAF1/CIP1 expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat 61: 33-43, 2000

    Google Scholar 

  10. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Palma PD, Harris AL, Barbareschi M: Prognostic value of p21WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res2: 1591-1599, 1996

    Google Scholar 

  11. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997

    Google Scholar 

  12. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 1997

    Google Scholar 

  13. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57: 1259-1263, 1997

    Google Scholar 

  14. Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet J-S, Narod SA, Slingerland J, Foulkes WD: Germline BRCA1/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol 18: 4045-4052, 2000

    Google Scholar 

  15. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C, Pirker R: Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 8: 729-733, 2002

    Google Scholar 

  16. Bartkova J, Lukas J, Strauss M, Bartek J: Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 17: 1027-1037, 1998

    Google Scholar 

  17. Doglioni C, Chiarelli C, Macri E, Dei Tos AP, Meggiolaro E, Dalla Palma P, Barbareschi M: Cyclin D3 expression in normal, reactive and neoplastic tissue. J Pathol 185: 159-166, 1998

    Google Scholar 

  18. Schmidt M, Lu Y, Parant JM, Lozano G, Bacher G, Beckers T, Fan Z: Differential roles of p21Waf1 and p27Kip1 in modulating chemosensitivity and their possible application in drug discovery studies. Mol Pharm 60: 900-906, 2001

    Google Scholar 

  19. Koepp DM, Harper JW, Elledge SJ: How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 97: 431-434, 1999

    Google Scholar 

  20. Sjöström J, Blomqvist C, Heikkilä P, Boguslawski v K, Räisänen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmström P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E: Predictive value of p53, mdm-2, p21, and p21Waf1, p27Kip1, p53, cyclin D3 and Ki-67 in breast cancer 103 mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6: 3103-3110, 2000

    Google Scholar 

  21. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Nat Cancer Inst 20: 1383-1387, 1989

    Google Scholar 

  22. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelenat H, Pouillart P: Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 29: 1843-1848, 1993

    Google Scholar 

  23. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinomas. Cancer 89: 2145-2152, 2000

    Google Scholar 

  24. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063, 1999

    Google Scholar 

  25. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P, Dogliotti L: Relationship between tumour shrinkage and reduction in Ki-67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85: 1106-1112, 2001

    Google Scholar 

  26. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, Andreola S, Silvestrini R, Di Fronzo G, Valagussa P: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Nat Cancer Inst 82: 1539-1545, 1990

    Google Scholar 

  27. Mauriac L, Durand M, Avril A, Dilhuydy JM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2: 347-354, 1991

    Google Scholar 

  28. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999

    Google Scholar 

  29. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298: 1223-1228, 1978

    Google Scholar 

  30. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Division of Oncology, University Hospital, Vienna, Austria

    Gudrun Pohl, Thomas Stranzl, Günther G. Steger, Robert Pirker & Martin Filipits

  2. Department of Clinical Pathology, University Hospital, Vienna, Austria

    Margaretha Rudas

  3. Department of Surgery, University Hospital, Vienna, Austria

    Susanne Taucher & Raimund Jakesz

Authors
  1. Gudrun Pohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaretha Rudas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susanne Taucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Stranzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Günther G. Steger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raimund Jakesz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert Pirker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Martin Filipits
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pohl, G., Rudas, M., Taucher, S. et al. Expression of Cell Cycle Regulatory Proteins in Breast Carcinomas Before and After Preoperative Chemotherapy. Breast Cancer Res Treat 78, 97–103 (2003). https://doi.org/10.1023/A:1022165715043

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022165715043

Search

Navigation